FDA warned Bodywell Natural Skin Care that its OTC hand sanitizer and Dermalere creams were adulterated due to CGMP failures and unapproved drug claims.
What happened
FDA reviewed records Bodywell submitted after FDA’s February 8, 2023 request for records under section 704(a)(4); no inspection dates are stated. FDA found missing component identity testing, including no methanol testing of ethanol for hand sanitizer, no finished-product release testing, no process validation, and incomplete batch records. It also found the Dermalere creams were unapproved new drugs based on wound-healing and anti-inflammatory claims.
What FDA found
Bodywell did not test incoming ingredients to confirm identity and did not verify its suppliers’ test results, including no methanol testing of ethanol used in hand sanitizer.
21 CFR 211.84(d)(1) and (2)Bodywell did not test each finished batch for active ingredient identity and strength before release.
21 CFR 211.165(a)Bodywell did not establish adequate written production and process controls or show its processes were validated.
21 CFR 211.100(a)Bodywell’s batch records lacked sampling details, yield calculations, and signatures for people performing and supervising steps.
21 CFR 211.188(b)FDA says the Dermalere creams are unapproved new drugs because their labels and website claim wound healing and treatment of inflammation.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a), 331(d)
What FDA wants
FDA tells Bodywell to correct the violations promptly and respond in writing within 15 working days with what it has done and plans to prevent recurrence. If it intends to resume U.S. drug manufacturing, FDA recommends a qualified CGMP consultant and a six-system audit before resuming.
Who should pay attention
- brands and distributors selling hand sanitizers or skin creams made by Bodywell
- U.S. importers of Canadian OTC drugs
- contract manufacturers relying on supplier COAs without identity testing
This is a summary. Read the original letter on fda.gov.